Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients

European Urology

Volumn 67, Issue 1, 2015, Pages 23-29

  Azad, Arun A ^a   Eigl, Bernhard J ^a   Murray, R Nevin ^a   Kollmannsberger, Christian ^a   Chi, Kim N ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Abiraterone; Abiraterone acetate; Castration resistant prostate cancer; Docetaxel; Enzalutamide

Indexed keywords

ABIRATERONE ACETATE; CABOZANTINIB; CEDIRANIB; DACTOLISIB; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SONOLISIB; 17-(3-PYRIDYL)-5,16-ANDROSTADIEN-3BETA-ACETATE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN; TAXOID;

AGED; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; ANALOGS AND DERIVATIVES; BLOOD; BONE NEOPLASMS; DISEASE COURSE; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROSTENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DISEASE PROGRESSION; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PHENYLTHIOHYDANTOIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE; TAXOIDS;

EID: 84926142870     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.06.045     Document Type: Article

References (30)

1. A. Heidenreich, D. Pfister, A. Merseburger, and G. Bartsch Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know Eur Urol 64 2013 260 265
2. T.M. Beer, A.J. Armstrong, and C.N. Sternberg Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study [abstract LBA1] J Clin Oncol 32 2014 (Suppl 4)
3. C.J. Ryan, M.R. Smith, and J.S. de Bono Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
4. A.J. Schrader, M. Boegemann, and C.H. Ohlmann Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone Eur Urol 65 2014 30 36
5. D. Bianchini, D. Lorente, and A. Rodriguez-Vida Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone Eur J Cancer 50 2014 78 84
6. F.B. Thomsen, M.A. Roder, P. Rathenborg, K. Brasso, M. Borre, and P. Iversen Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate Scand J Urol 48 2014 268 275
7. S.C. Schmid, A. Geith, and A. Boker Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer Adv Ther 31 2014 234 241
8. S. Badrising, V. van der Noort, and I.M. van Oort Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment Cancer 120 2014 968 975
9. H.H. Cheng, R. Nadal, and R. Gulati The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC [abstract 18] J Clin Oncol 32 2014 (Suppl 4)
10. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
11. C.N. Sternberg, J.S. de Bono, and K.N. Chi Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial Ann Oncol 25 2014 429 434
12. R.R. Zielinski, S. Tyldesley, and K.N. Chi Population-based impact on overall survival (OS) after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer (CRPC) [abstract 77] J Clin Oncol 31 2013 (Suppl 6)
13. NIH-funded study shows increased survival in men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy [news release]. National Cancer Institute Web site. http://www.nih.gov/news/health/dec2013/nci-05.htm.
14. B. Cao, Y. Qi, and G. Zhang Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy Oncotarget 30 2014 1646 1656
15. J.D. Joseph, N. Lu, and J. Qian A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509 Cancer Discov 3 2013 1020 1029
16. M. Korpal, J.M. Korn, and X. Gao An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide) Cancer Discov 3 2013 1030 1043
17. H. Matsumoto, Y. Yamamoto, and M. Shiota Cotargeting androgen receptor and clusterin delays castrate-resistant prostate cancer progression by inhibiting adaptive stress response and AR stability Cancer Res 73 2013 5206 5217
18. M. Shiota, A. Yokomizo, and A. Takeuchi Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer Clin Cancer Res 20 2014 951 961
19. V.K. Arora, E. Schenkein, and R. Murali Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade Cell 155 2013 1309 1322
20. E.S. Antonarakis, and A.J. Armstrong Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer Prostate Cancer Prostatic Dis 14 2011 192 205
21. R.J. van Soest, M.E. van Royen, and E.S. de Morree Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer Eur J Cancer 49 2013 3821 3830
22. K.L. Noonan, S. North, R.L. Bitting, A.J. Armstrong, S.L. Ellard, and K.N. Chi Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide Ann Oncol 24 2013 1802 1807
23. Y. Loriot, D. Bianchini, and E. Ileana Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Ann Oncol 24 2013 1807 1812
24. Antonarakis ES, Lu C, Wang H, et al. Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC) [abstract 5001]. J Clin Oncol 2014; 32:5s(Suppl).
25. H.I. Scher, K. Fizazi, and F. Saad Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor [abstract 6] J Clin Oncol 31 2013 (Suppl 6)
26. J. Goyal, P. Nuhn, and P. Huang The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer BJU Int 110 2012 E575 E582
27. C.J. Ryan, A. Molina, and J. Li Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial J Clin Oncol 31 2013 2791 2798
28. J.S. de Bono, H.I. Scher, and R.B. Montgomery Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res 14 2008 6302 6309
29. D. Olmos, H.T. Arkenau, and J.E. Ang Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience Ann Oncol 20 2009 27 33
30. H.I. Scher, X. Jia, and J.S. de Bono Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data Lancet Oncol 10 2009 233 239